Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Nevro Corp (NVRO)

Nevro Corp (NVRO)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 4,718,379
  • Shares Outstanding, K 34,313
  • Annual Sales, $ 390,260 K
  • Annual Income, $ -103,690 K
  • 60-Month Beta 0.94
  • Price/Sales 11.49
  • Price/Cash Flow N/A
  • Price/Book 11.98

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 12 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/20
See More
  • Average Estimate -0.61
  • Number of Estimates 7
  • High Estimate -0.39
  • Low Estimate -0.94
  • Prior Year -0.58
  • Growth Rate Est. (year over year) -5.17%

Price Performance

See More
Period Period Low Period High Performance
1-Month
111.99 +24.43%
on 07/14/20
145.30 -4.09%
on 08/06/20
+24.48 (+21.31%)
since 07/13/20
3-Month
111.87 +24.56%
on 07/09/20
145.30 -4.09%
on 08/06/20
+21.22 (+17.96%)
since 05/13/20
52-Week
65.05 +114.22%
on 03/23/20
148.05 -5.88%
on 02/26/20
+58.31 (+71.95%)
since 08/13/19

Most Recent Stories

More News
Global Neurostimulation Devices Market: Analysis and Forecast, 2021-2030

, /PRNewswire/ -- Market Segmentation• By Product Type: Implantable and non-implantableImplantable neurostimulation devices can be further segmented into seven types - spinal cord stimulation, auditory...

ABT : 101.19 (+0.54%)
BSX : 39.88 (-0.20%)
HSDT : 0.4900 (+4.26%)
LIVN : 48.57 (-0.51%)
MDT : 101.48 (-0.60%)
NVRO : 139.61 (+1.53%)
NVTR : 0.13 (-23.17%)
Nevro (NVRO) Q2 Loss Narrower than Expected, Revenues Beat

Nevro's (NVRO) domestic and international revenues declined on a year-over-year basis in Q2.

PKI : 120.06 (+0.16%)
TMO : 416.56 (+0.09%)
OPK : 4.92 (+4.24%)
NVRO : 139.61 (+1.53%)
Nevro to Present at Canaccord Genuity 40th Annual Virtual Growth Conference

, /PRNewswire/ -- Nevro Corp. (NYSE: NVRO), a global medical device company that is providing innovative, evidence-based solutions for the treatment of chronic pain, today announced that D. , Nevro's...

NVRO : 139.61 (+1.53%)
SmarTrend Watching for Potential Pullback in Shares of Nevro Corp After 2.50% Gain

Nevro Corp (NYSE:NVRO) traded in a range yesterday that spanned from a low of $135.39 to a high of $145.30. Yesterday, the shares gained 2.5%, which took the trading range above the 3-day high of $138.14...

NVRO : 139.61 (+1.53%)
Nevro (NVRO) Reports Q2 Loss, Tops Revenue Estimates

Nevro (NVRO) delivered earnings and revenue surprises of 26.67% and 36.02%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?

NVRO : 139.61 (+1.53%)
Nevro: 2Q Earnings Snapshot

REDWOOD CITY, Calif. (AP) _ Nevro Corp. (NVRO) on Wednesday reported a loss of $41.1 million in its second quarter.

NVRO : 139.61 (+1.53%)
ABIOMED (ABMD) to Report Q1 Earnings: What's in the Offing?

The commercial rollout of ABIOMED's (ABMD) Impella 5.5 is expected to have progressed steadily through the fiscal first quarter.

IART : 51.73 (+1.79%)
ABMD : 309.06 (+2.22%)
GWPH : 107.89 (-1.02%)
NVRO : 139.61 (+1.53%)
DENTSPLY SIRONA (XRAY) to Post Q2 Earnings: What's in Store?

DENTSPLY SIRONA's (XRAY) second-quarter results are likely to reflect weak segmental performance.

XRAY : 44.68 (-0.62%)
IART : 51.73 (+1.79%)
GWPH : 107.89 (-1.02%)
NVRO : 139.61 (+1.53%)
Cardinal Health (CAH) to Post Q4 Earnings: What's in Store?

Cardinal Health's (CAH) fiscal fourth-quarter results are likely to reflect solid performance in Medical segment.

CAH : 52.85 (-1.80%)
IART : 51.73 (+1.79%)
GWPH : 107.89 (-1.02%)
NVRO : 139.61 (+1.53%)
What's in Store for Becton, Dickinson's (BDX) Q3 Earnings?

Becton, Dickinson's (BDX) fiscal third-quarter results likely to reflect robust performance at BD Life Sciences. However, forex is likely to have remained a woe.

BDX : 262.34 (+1.99%)
IART : 51.73 (+1.79%)
GWPH : 107.89 (-1.02%)
NVRO : 139.61 (+1.53%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Buy with a Strongest short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Trade NVRO with:

Business Summary

Nevro Corp. is a medical device company. It engages in developing and commercializing a neuromodulation platform for the treatment of chronic pain. The Company provides pain relief to the customers suffering from low back pain and types of chronic pains. Nevro has developed and commercialized the Senza...

See More

Key Turning Points

2nd Resistance Point 142.24
1st Resistance Point 139.87
Last Price 139.61
1st Support Level 133.25
2nd Support Level 129.00

See More

52-Week High 148.05
Last Price 139.61
Fibonacci 61.8% 116.34
Fibonacci 50% 106.55
Fibonacci 38.2% 96.76
52-Week Low 65.05

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar